oxybutynin
oxybutynin: sourced relationships with 1 company · 1 clinical trial tracked · 2 FDA decisions.
oxybutynin evidence translation
What we can confirm
2 FDA records · 1 tracked trial
What it means
What to watch
Prepared research question
How could oxybutynin → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| AbbVie Inc. (ABBV) Reported 2009-01-27 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms
Primary endpoint: Mean change from baseline to week 12 in symptom bother measured by the Menopause-Specific Quality of Life Domain (MENQoL) 1-week recall VMS domain score
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with oxybutynin?
oxybutynin has dated SEC/FDA relationship records for AbbVie Inc..
How many clinical trials involve oxybutynin?
BioSniper tracks 1 clinical trial involving oxybutynin.
What is oxybutynin's latest FDA decision?
The most recent tracked FDA decision for oxybutynin is Approval for Use treats overactive bladder in women you may be suffering from overactive bladder if you have had 2 or more of the following symptoms for at least 3 months: ○ urinary frequency (the need to urinate more often than usual; typically more than 8 times in 24 hours) ○ urinary urgency (a strong need to urinate right away) ○ urge incontinence (leaking or wetting yourself if you cannot control the urge to urinate) non-drug therapies may also help you (see the consumer information leaflet inside the pa, dated January 25, 2013.